Artículos de revistas
Racotumomab for treating lung cancer and pediatric refractory malignancies
Fecha
2016-01Registro en:
Gabri, Mariano Rolando; Cacciavillano, Walter; Chantada, Guillermo Luis; Alonso, Daniel Fernando; Racotumomab for treating lung cancer and pediatric refractory malignancies; Taylor & Francis; Expert Opinion on Biological Therapy; 16; 4; 1-2016; 573-578
1471-2598
CONICET Digital
CONICET
Autor
Gabri, Mariano Rolando
Cacciavillano, Walter
Chantada, Guillermo Luis
Alonso, Daniel Fernando
Resumen
Introduction: Racotumomab (originally known as 1E10 mAb) is an anti-idiotype murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid tumors. It was developed as a mirror image of the idiotype of another antibody against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. After a successful phase II/III study, racotumomab formulated in alum was conditionally approved in Latin American countries as maintenance therapy for advanced non-small cell lung cancer. Areas covered: This review analyzes the biology of the target antigen, summarizes preclinical studies and discusses clinical trials in adults and the pediatric experience with racotumomab. Expert opinion: Proper patient selection and combination with chemotherapy, radiotherapy or checkpoint inhibitors appear to be critical issues to maximize the effects of racotumomab vaccination in lung cancer. In a recent phase I clinical trial in children with relapsed or resistant neuroectodermal malignancies, racotumomab was well tolerated and immunogenic, and its evaluation as immunotherapy for high-risk neuroblastoma is warranted.